Show the full website


Emergency loan keeps biotech firm afloat – crucial to staying operational

The Biotech company Acesion Pharma has taken up a Covid-19 emergency loan worth DKK 20m from the Danish Growth Fund to keep the engines running. An important phase II study has been postponed by at least six months, according to the firm's executive chairman.

Foto: Novo Holdings / PR

The Copenhagen-based Biotech Acesion Pharma has requested – and received – an emergency loan worth DKK 20m from the Danish Growth Fund, which will keep the company afloat during the Covid-19 pandemic.

This has been registered in the Danish Central Business Register, and the firm's chairman of the board of directors affirms the information:

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

Receive newsletter from MedWatch today

NB: Subscribing to the newsletter is free.

More from MedWatch


See all jobs